Epigenica has developed a platform that enables epigenetic profiling on a much larger scale than has previously been possible. The quantitative and multiplex technology can analyze both DNA methylation and histone modifications, which creates a fast and cost-effective analysis. The technology will, among other things, facilitate research in cancer therapy, drug development, epigenetic diagnostics, precision medicine and discoveries of new biomarkers.


Visit site